MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.

doi:10.1016/j.jtho.2023.06.020

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2024

Riedel Richard, Fassunke Jana, Scheel Andreas H, Scheffler Matthias, Heydt Carina, Nogova Lucia, Michels Sebastian, Fischer Rieke N, Eisert Anna, Scharpenseel Heather, John Felix, Ruge Lea, Schaufler Diana, Siemanowski Janna, Ihle Michaela A, Wagener-Ryczek Svenja, Pappesch Roberto, Rehker Jan, Bunck Anne, Kobe Carsten, Keil Felix, Merkelbach-Bruse Sabine, Büttner Reinhard, Wolf Jürgen

Abstract excerpt

INTRODUCTION: MET fusions have been described only rarely in NSCLC. Thus, data on patient characteristics and treatment response are limited. We here report histopathologic data, patient demographics, and treatment outcome including response to MET tyrosine kinase inhibitor (TKI) therapy in MET fusion-positive NSCLC. METHODS: Patients with NSCLC and MET fusions were identified mostly by RNA sequencing within the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Liver physiology and pathology

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Melanoma and MAPK Pathways

Share to Mutation

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 37429463
DOI: 10.1016/j.jtho.2023.06.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.PMID 37429463Read ↗

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer.Semantic proximity Read ↗

MET fusions are targetable genomic variants in the treatment of advanced malignancies.Semantic proximity Read ↗

Molecular characterization of MET fusions from a large real-world Chinese population: A multicenter study.Semantic proximity Read ↗

Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapySemantic proximity Read ↗

The METeoric rise of MET in lung cancerSemantic proximity Read ↗

Unveiling the Uncommon: Targeting Rare MET Fusions in NSCLC: A Comprehensive ReviewSemantic proximity Read ↗

Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.Semantic proximity Read ↗

Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.Semantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Analysis of MET kinase domain rearrangement in NSCLC.Semantic proximity Read ↗

Oncogenic Fusions in NSCLC: From Mechanisms to Clinical ApplicationsSemantic proximity Read ↗

Clinically relevant fusion oncogenes: detection and practical implicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.